Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have received a consensus rating of “Buy” from the seven research firms that are presently covering the firm. One equities research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $21.33.
VNDA has been the topic of a number of research reports. Piper Jaffray Companies set a $19.00 price objective on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 24th. Zacks Investment Research raised Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $17.00 price objective on the stock in a report on Tuesday, November 8th. Aegis initiated coverage on Vanda Pharmaceuticals in a report on Wednesday, November 9th. They set a “buy” rating and a $24.00 price objective on the stock. Finally, Jefferies Group LLC reissued a “buy” rating and set a $23.00 price objective on shares of Vanda Pharmaceuticals in a report on Sunday, January 8th.
In other news, SVP Richard L. Gulino sold 10,900 shares of the business’s stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $15.51, for a total transaction of $169,059.00. Following the transaction, the senior vice president now directly owns 12,500 shares of the company’s stock, valued at $193,875. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 8.45% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Acrospire Investment Management LLC boosted its position in Vanda Pharmaceuticals by 18.1% in the third quarter. Acrospire Investment Management LLC now owns 9,894 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 1,516 shares during the period. Capital One National Association acquired a new position in Vanda Pharmaceuticals during the third quarter valued at about $320,000. Smith Asset Management Group LP purchased a new stake in Vanda Pharmaceuticals during the third quarter valued at $348,000. Birchview Capital LP purchased a new stake in Vanda Pharmaceuticals during the fourth quarter valued at $351,000. Finally, Virginia Retirement Systems ET AL purchased a new stake in Vanda Pharmaceuticals during the third quarter valued at $361,000. 95.74% of the stock is currently owned by hedge funds and other institutional investors.
Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 14.30 on Thursday. Vanda Pharmaceuticals has a 12-month low of $6.95 and a 12-month high of $18.00. The firm’s 50 day moving average price is $14.38 and its 200-day moving average price is $15.02. The company’s market capitalization is $628.43 million.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/analysts-set-vanda-pharmaceuticals-inc-vnda-target-price-at-21-33/1656344.html
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.